MedTrace Logo

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

NCT02048059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-02-25

No results posted yet for this study

Summary

This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.

Conditions

Interventions

DRUG

ANG1005

Sponsors & Collaborators

  • Angiochem Inc

    lead INDUSTRY

Principal Investigators

  • Betty Lawrence · Angiochem Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-03-31
Completion
2017-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02048059 on ClinicalTrials.gov